OR WAIT null SECS
Thermo Fisher Scientific has launched its first GMP-manufactured Cas9 protein for clinical genome editing research.
Thermo Fisher Scientific has introduced its new GMP-manufactured Gibco CTA TrueCut Cas9 protein to support genome editing for research and manufacturing applications. The proteins are manufactured with United States Pharmacopeia (USP) standards in mind, including traceability documentation, aseptic manufacturing, and safety testing.
High-quality ancillary materials and documentation are critical as researchers using genome editing tools move from basic research to clinical settings, including Chimeric antigen receptor (CAR) T-cell therapy research. The Gibco CTS TrueCut Cas9 protein provides greater than 90% efficacy in human primary T-cells, making it a promising solution for CAR T-cell therapy research, according to the company. Along with the company’s recently launched Gibco CTS Xenon Electroporation System, the GMP-manufactured Cas9 protein can aid Thermo Fisher in supporting researchers across the autologous T-cell workflow.
"As genome editing quality and regulatory requirements continue to evolve, we are focused on providing solutions to meet scientists' needs as they transition from the bench to the clinic," said Brandon Pence, vice president and general manager of cell biology at Thermo Fisher Scientific, in a press release. "By adding the Gibco CTS TrueCut Cas9 Protein to our portfolio of genome editing solutions, we can now support scientists in their journey to develop personalized CAR T-cell therapeutics."
Source: Thermo Fisher Scientific